Clinical Trials
Prophylactic HFNC reduces pulmonary complications after lung resection in trial
Lin et alCritical care (London, England)

In a single-center, open-label randomized controlled trial, investigators evaluated whether prophylactic high-flow nasal cannula (HFNC) reduces postoperative pulmonary complications (PPCs) compared with conventional oxygen therapy (COT) in older patients undergoing lung resection. The study enrolled patients with stage I to IIIa non-small cell lung cancer (NSCLC) undergoing video-assisted thoracoscopic surgery (VATS) lobectomy or segmentectomy. A total of 210 patients were analyzed in the modified intention-to-treat cohort (n = 104 in the HFNC arm and n = 106 in the COT arm).
The primary outcome evaluated PPC severity during hospitalization using ordinal logistic regression and compared the incidence of clinically relevant PPCs (grade ≥ 2). Secondary endpoints assessed longitudinal respiratory symptoms (via mMRC, LCQ-MC, and sCSS) and symptom-related functional interference (via MDASI-LC) using mixed-effects models.
Prophylactic HFNC demonstrated a statistically significant reduction in PPC severity relative to COT (ordinal OR, 0.50; 95% CI, 0.28–0.91; P = 0.022). Patients receiving HFNC also experienced a lower rate of moderate-to-severe (grade ≥ 2) PPCs compared with those receiving conventional oxygen (23.1% vs. 39.6%; absolute risk difference, -15.6%; 95% CI, -28.0% to -3.2%; P = 0.010). Furthermore, secondary analyses indicated favorable trajectories in early postoperative respiratory symptoms and functional recovery scores. However, the intervention did not produce significant differences in physiological measures or overall hospital length of stay. The study authors concluded that prophylactic HFNC may serve as a beneficial respiratory support strategy in selected older or higher-risk patients undergoing thoracic surgery, though routine unselected implementation is not supported.
Key Takeaways
- Prophylactic high-flow nasal cannula significantly reduced postoperative pulmonary complication severity compared with conventional oxygen therapy (ordinal OR, 0.50; 95% CI, 0.28–0.91; P = 0.022).
- High-flow nasal oxygen reduced the incidence of moderate-to-severe postoperative pulmonary complications from 39.6% to 23.1% (absolute risk difference, -15.6%; 95% CI, -28.0% to -3.2%; P = 0.010).
- Secondary analyses demonstrated improved early postoperative respiratory symptoms and functional interference with high-flow oxygen, but no differences were observed in physiological outcomes or hospital length of stay.
Read the original sourceCritical care (London, England)
